MECP2 and Rett syndrome: Finally, an in vivo treatment with a GABA reuptake inhibitor significantly improved the lifespan of Mecp2-deficient mice suggesting that the modulation of the GABAergic pathway may be a new therapeutic target for the treatment of RTT-associated clinical signs.